Patel, Rupesh S.
Romero, Rodrigo http://orcid.org/0000-0002-9388-8306
Watson, Emma V.
Liang, Anthony C.
Burger, Megan http://orcid.org/0000-0003-4880-7260
Westcott, Peter M. K.
Mercer, Kim L. http://orcid.org/0000-0002-8525-483X
Bronson, Roderick T.
Wooten, Eric C.
Bhutkar, Arjun
Jacks, Tyler http://orcid.org/0000-0001-5785-8911
Elledge, Stephen J. http://orcid.org/0000-0001-7923-6283
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (CA234600)
Article History
Received: 22 July 2021
Accepted: 6 December 2021
First Online: 11 January 2022
Competing interests
: S.J.E. is a co-founder of TSCAN Therapeutics, MAZE Therapeutics and Mirimus, ImmuneID, S.J.E. serves on the Scientific Advisory Board of CRISPR Therapeutics, Homology Medicines, Inc., TSCAN Therapeutics, XChem, and is an advisor for MPM. T.J. is the president of Break Through Cancer and is a member of the Board of Directors of Amgen and Thermo Fisher Scientific. He is also a co-Founder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech, and Skyhawk Therapeutics. None of these affiliations represent a conflict of interest with respect to the design or execution of this study or interpretation of data presented in this manuscript. T.J. laboratory receives funding from the Johnson & Johnson Lung Cancer Initiative and Calico Life Sciences LLC, but this funding did not support the research described in this manuscript. The remaining authors declare no competing interests.